Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2022-04-29 Share Issue/Capital Cha…
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Antal aktier och röster i Calliditas Therapeutics
Share Issue/Capital Change Classification · 98% confidence The document is a short press release dated April 29, 2022, from Calliditas Therapeutics. The core content announces a change in the total number of outstanding shares and votes due to the issuance of shares from a stock option program. This directly relates to a change in the company's capital structure or share count. The most fitting category is 'Share Issue/Capital Change' (SHA). It is not a general regulatory filing (RNS) because it fits a specific category, and it is not a dividend notice (DIV) or director dealing (DIRS). The length is short, but the content is a direct announcement of a capital change, not just an announcement *about* a report.
2022-04-29 Swedish
Annual Report (ESEF) 2021
Annual Report (ESEF) Classification · 100% confidence FY 2021
2022-04-27 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (Swedbank Robur Fonder AB) in the issuer (Calliditas Therapeutics AB). It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities and voting rights, noting the 'Reason for major shareholding notification Sell' and the resulting percentage (4.97%). This structure perfectly matches the definition of a Major Shareholding Notification, which tracks when ownership crosses specified thresholds. The corresponding code is MRQ.
2022-04-22 English
Notice of annual general meeting of Calliditas Therapeutics AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled 'Notice of annual general meeting of Calliditas Therapeutics AB (publ)' and details the procedures for shareholders to participate via advance voting, the proposed agenda items (including election of directors, approval of remuneration, and resolutions on share issues), and specific dates related to the meeting (May 19, 2022). This content directly corresponds to the materials distributed to shareholders in preparation for an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information). The document length is substantial (58k chars), confirming it is the primary material, not just a brief announcement of publication.
2022-04-14 English
Kallelse till årsstämma i Calliditas Therapeutics AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Calliditas Therapeutics AB (publ)" which translates to "Notice of Annual General Meeting in Calliditas Therapeutics AB (publ)". It explicitly calls shareholders to the Annual General Meeting (årsstämma) on May 19, 2022, and details the procedures for advance voting (förhandsröstning) due to temporary exceptions. The proposed agenda items (dagordning) cover standard AGM topics like election of the chairman, approval of remuneration reports, and authorization for share issues. This content directly corresponds to the purpose of an Annual General Meeting notice/materials.
2022-04-14 Swedish
Earnings Release 2021
Earnings Release Classification · 96% confidence The document is titled "Q4 2021 BOKSLUTSKOMMUNIKÉ JANUARI – DECEMBER 2021" (Q4 2021 YEAR-END COMMUNICATION JANUARY – DECEMBER 2021) and presents key financial figures for the fourth quarter and the full year 2021 (October 1 - December 31, 2021, and January 1 - December 31, 2021). It also discusses significant events, such as the FDA approval of TARPEYO™. The structure, including key figures, summary of events, and CEO commentary, strongly indicates a periodic financial results announcement. Since it covers a full quarter and year-end, it is more comprehensive than a typical Earnings Release (ER) which focuses only on highlights. However, the Swedish title 'BOKSLUTSKOMMUNIKÉ' often translates to a preliminary earnings release or a year-end summary, which aligns closely with the 'Earnings Release' (ER) definition, especially when compared to the comprehensive 'Interim/Quarterly Report' (IR) which is usually for half-years or specific interim periods, or the '10-K' which is the official annual filing. Given the focus on summarizing the period's results and major achievements (like the FDA approval) immediately following the period end, 'ER' (Earnings Release) is the most appropriate classification for this type of preliminary/summary communication, even if it covers the full year. The document length is substantial (98k chars), suggesting it is more than just a brief announcement, but the content is structured as the initial release of results. Q4 2021
2022-02-24 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.